Meridian Medical Technologies has been granted the Department of Homeland Security (DHS) SAFETY Act Designation and Certification for its portfolio of medical countermeasures intended for the treatment of chemical nerve agent exposure or for the management of pain. The designation and certification, granted after an extensive application process, validates the company’s leadership in providing emergency care products to military and civilian defenders and first responders.
Meridian Medical Technologies provides ATNAA, Diazepam, DuoDote, Pralidoxime Chloride, AtroPen, and Morphine Auto-injectors. The technology is a series of ready-to-use, pre-filled auto-injectors intended for the treatment of chemical nerve agent exposure or for the management of pain. The technology is approved for use by the Food and Drug Administration. It also includes packaging, stockpile storage of sterile auto-injector assemblies, stockpile storage of medical solutions, training auto-injectors and the associated use protocols, labeling and package inserts. This Designation and Certification will expire on October 31, 2021.
Meridian Medical Technologies has been putting emergency care treatment options into the hands of military and civilian defenders for more than 50 years. Meridian is committed to help defend against critical, time-sensitive, life-or-death situations by providing medical countermeasures to the Department of Defense, Emergency Medical Services, DHS and more than 30 nations around the world.
